A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform
暂无分享,去创建一个
S. Steinberg | W. Figg | D. Liewehr | W. Dahut | J. Deeken | D. Price | T. Sissung | X. Miao | K. Tran | T. Cormier | William L Dahut | Seth M. Steinberg
[1] A. Morris,et al. A single nucleotide polymorphism on exon-4 of the gene encoding PPARdelta is associated with reduced height in adults and children. , 2009, The Journal of clinical endocrinology and metabolism.
[2] A. Morris,et al. A Single Nucleotide Polymorphism on Exon-4 of the Gene Encoding PPAR (cid:1) Is Associated with Reduced Height in Adults and Children , 2009 .
[3] Elmar Bucher,et al. Genome‐wide analysis identifies 16q deletion associated with survival, molecular subtypes, mRNA expression, and germline haplotypes in breast cancer patients , 2008, Genes, chromosomes & cancer.
[4] S. Steinberg,et al. ABCB1 Genetic Variation Influences the Toxicity and Clinical Outcome of Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel , 2008, Clinical Cancer Research.
[5] Francis J McMahon,et al. Association study of Wnt signaling pathway genes in bipolar disorder. , 2008, Archives of general psychiatry.
[6] S. Steinberg,et al. Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel , 2008, Molecular Cancer Therapeutics.
[7] M. Maitland,et al. Interpreting P values in pharmacogenetic studies: a call for process and perspective. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] D. Venzon,et al. Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer. , 2007, Urology.
[9] Philip Hahnfeldt,et al. Transcriptional network governing the angiogenic switch in human pancreatic cancer , 2007, Proceedings of the National Academy of Sciences.
[10] A. Krook,et al. Role of AMP Kinase and PPARδ in the Regulation of Lipid and Glucose Metabolism in Human Skeletal Muscle* , 2007, Journal of Biological Chemistry.
[11] D. Schaid,et al. Genetic diversity and function in the human cytosolic sulfotransferases , 2007, The Pharmacogenomics Journal.
[12] A. El-Husseini,et al. NIPA1(SPG6), the Basis for Autosomal Dominant Form of Hereditary Spastic Paraplegia, Encodes a Functional Mg2+ Transporter* , 2007, Journal of Biological Chemistry.
[13] P. Hardenbol,et al. Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix Targeted Genotyping System. , 2007, Pharmacogenomics.
[14] S. Bates,et al. Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics , 2007, Anti-cancer drugs.
[15] W. M. Smit,et al. Pharmacogenetic Screening of CYP3A and ABCB1 in Relation to Population Pharmacokinetics of Docetaxel , 2006, Clinical Cancer Research.
[16] S. Bates,et al. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib , 2006, Clinical pharmacology and therapeutics.
[17] W. Figg,et al. Thalidomide metabolism and hydrolysis: mechanisms and implications. , 2006, Current drug metabolism.
[18] C. Chau,et al. Heterogeneity in drug disposition determines interindividual variability of docetaxel pharmacokinetics , 2006, Cancer biology & therapy.
[19] J. Verweij,et al. Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel , 2006, Cancer biology & therapy.
[20] F. Goldwasser,et al. Pharmacokinetics and toxicity of docetaxel: Role of CYP3A, MDR1, and GST polymorphisms , 2006, Clinical pharmacology and therapeutics.
[21] M. Laakso,et al. Single nucleotide polymorphisms in the peroxisome proliferator-activated receptor delta gene are associated with skeletal muscle glucose uptake. , 2005, Diabetes.
[22] S. Bates,et al. Effect of Common CYP3A4 and CYP3A5 Variants on the Pharmacokinetics of the Cytochrome P450 3A Phenotyping Probe Midazolam in Cancer Patients , 2005, Clinical Cancer Research.
[23] J. Chang,et al. Prediction of Docetaxel Response in Human Breast Cancer by Gene Expression Profiling , 2005 .
[24] R. Hume,et al. Expression profiling of human fetal cytosolic sulfotransferases involved in steroid and thyroid hormone metabolism and in detoxification , 2005, Molecular and Cellular Endocrinology.
[25] T. Thalhammer,et al. Altered expression of the hormone- and xenobiotic-metabolizing sulfotransferase enzymes 1A2 and 1C1 in malignant breast tissue. , 2005, International journal of oncology.
[26] S. Howell,et al. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. , 2005, Critical reviews in oncology/hematology.
[27] C. Baines,et al. Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR. , 2004, International journal of epidemiology.
[28] B. Palmer,et al. Metabolism of Thalidomide in Liver Microsomes of Mice, Rabbits, and Humans , 2004, Journal of Pharmacology and Experimental Therapeutics.
[29] S. Steinberg,et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] F. Dalenc,et al. Dexamethasone as a probe for docetaxel clearance , 2004, Cancer Chemotherapy and Pharmacology.
[31] J. Verweij,et al. Effect of Cytochrome P450 3A4 Inhibition on the Pharmacokinetics of Docetaxel , 2004, Clinical pharmacology and therapeutics.
[32] René Bruno,et al. Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships for Docetaxel , 2001, Investigational New Drugs.
[33] T. Imai,et al. Effects of NO-1886 (Ibrolipim), a lipoprotein lipase-promoting agent, on gene induction of cytochrome P450s, carboxylesterases, and sulfotransferases in primary cultures of human hepatocytes. , 2004, Drug metabolism and pharmacokinetics.
[34] A. Hamsten,et al. Evidence That Peroxisome Proliferator–Activated Receptor Delta Influences Cholesterol Metabolism in Men , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[35] J. Boyer,et al. Bile salt transporters: molecular characterization, function, and regulation. , 2003, Physiological reviews.
[36] M. Miyata,et al. Thalidomide-induced suppression of embryo fibroblast proliferation requires CYP1A1-mediated activation. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[37] J. Rigas,et al. Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[38] Y. Ando,et al. Pharmacogenetic Associations of CYP2C19 Genotype with In Vivo Metabolisms and Pharmacological Effects of Thalidomide , 2002, Cancer biology & therapy.
[39] S. Bates,et al. Single-Nucleotide Polymorphism (SNP) Analysis in the ABC Half-Transporter ABCG2 (MXR/BCRP/ABCP1) , 2002, Cancer biology & therapy.
[40] Zhe-Sheng Chen,et al. Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). , 2002, Cancer research.
[41] B. Goh,et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] W. Figg,et al. Thalidomide metabolism by the CYP2C subfamily. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[43] K. Tanimoto,et al. Cellular sensitivity determinants to docetaxel in human gastrointestinal cancers. , 2002, International Journal of Oncology.
[44] W. Figg,et al. 5´-OH-Thalidomide, a Metabolite of Thalidomide, Inhibits Angiogenesis , 2002, Therapeutic drug monitoring.
[45] A. Sekine,et al. Catalog of 77 single-nucleotide polymorphisms (SNPs) in the carbohydrate sulfotransferase 1 (CHST1) and carbohydrate sulfotransferase 3 (CHST3) genes , 2002, Journal of Human Genetics.
[46] H. Tamura,et al. Expression profiling of sulfotransferases in human cell lines derived from extra-hepatic tissues. , 2001, Biological & pharmaceutical bulletin.
[47] T. Tedder,et al. CHST1 and CHST2 sulfotransferase expression by vascular endothelial cells regulates shear‐resistant leukocyte rolling via l‐selectin , 2001, Journal of leukocyte biology.
[48] D. Hartmann,et al. Enzymatic properties, tissue-specific expression, and lysosomal location of two highly homologous rat SULT1C2 sulfotransferases. , 2000, Biochemical and biophysical research communications.
[49] P. Watkins,et al. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[50] P. Sabourin,et al. Metabolism of thalidomide in human microsomes, cloned human cytochrome P‐450 isozymes, and Hansen’s disease patients , 2000, Journal of biochemical and molecular toxicology.
[51] L. Rivory,et al. Clinical Pharmacokinetics of Docetaxel , 1999, Clinical pharmacokinetics.
[52] K. Korzekwa,et al. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. , 1998, Pharmacogenetics.
[53] Sergio Cocozza,et al. Spastic Paraplegia and OXPHOS Impairment Caused by Mutations in Paraplegin, a Nuclear-Encoded Mitochondrial Metalloprotease , 1998, Cell.
[54] L B Sheiner,et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] P. V. van Helden,et al. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. , 1997, American journal of respiratory and critical care medicine.
[56] J. Lo-Guidice,et al. NAT2 genotyping and efficacy of sulfasalazine in patients with chronic discoid lupus erythematosus. , 1997, Pharmacogenetics.
[57] J. Beijnen,et al. Isolation, purification and biological activity of major docetaxel metabolites from human feces. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[58] G. de Sousa,et al. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. , 1996, Cancer research.
[59] B. Monsarrat,et al. Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. , 1996, Cancer research.
[60] S. Weinreb,et al. Teratogen metabolism: spontaneous decay products of thalidomide and thalidomide analogues are not bioactivated by liver microsomes. , 1985, Teratogenesis, carcinogenesis, and mutagenesis.
[61] Nitin R. Patel,et al. A Network Algorithm for Performing Fisher's Exact Test in r × c Contingency Tables , 1983 .
[62] R. T. Williams,et al. The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution. , 1965, British journal of pharmacology and chemotherapy.